- RecruitingPHASE3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.
For: CLL · Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
This study looks at a new combination of three chemotherapy-free drugs for people newly diagnosed with Mantle Cell Lymphoma. It aims to see if this treatment can clear the cancer and if some people can then stop treatment or use just one drug.
For: Mantle Cell Lymphoma (MCL)United States · Australia · Brazil - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)
This study is looking at two medicines, venetoclax and azacitidine, to see if they can help people with a type of blood cancer called acute myeloid leukemia (AML) stay well after their first round of treatment. It's a key stage of research to check their safety and how well they work.
For: Acute Myeloid Leukemia in First RemissionGermany · Greece · Czechia - Active not recruitingPHASE3
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study is looking at two different medicine combinations for people with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). We want to see if a newer treatment works better at stopping the cancer from growing.
For: Leukemia, Lymphocytic, Chronic, B-CellUnited States · Belgium · Canada - AuthorisedPhase I and Phase II (Integrated)- Other
ABT-199 (Venetoclax) and Purine analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (ApoAML)
This study looks at new drug combinations for adults with Acute Myeloid Leukaemia (AML) that has come back or not responded to previous treatment. It tests venetoclax and mercaptopurine together to see how well they work and if they are safe.
For: Acute myeloid leukemiaBelgium - Active not recruitingPHASE3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
This study compares a new drug, zanubrutinib, with standard treatments (bendamustine and rituximab) for adults with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Researchers want to see which treatment works best to stop the cancer from getting worse.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesUnited States · Finland · United Kingdom - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Brazil - RecruitingPHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
This study looks at new drug combinations for adults in the UK with a type of blood cancer called chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It compares new treatments with current ones to see which works best and is safest for patients whose cancer has come back or not responded to previous treatments.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
For: Chronic Lymphocytic Leukemia · Acute Myeloid Leukemia · Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
Study to Evaluate the Safety and Tolerability of EP0042
This study is looking at a new treatment called EP0042 for advanced blood cancers like acute myeloid leukaemia (AML). It aims to find a safe and effective dose of EP0042, sometimes combined with other medicines, for patients whose cancer treatments haven't worked or have stopped working.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesAustralia · Netherlands · United Kingdom - Active not recruitingPHASE3
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
This study looks at a new drug, venetoclax, combined with existing treatment, azacitidine, for adults with a type of blood disorder called higher-risk Myelodysplastic Syndrome (MDS). It aims to see if this combination is safe and effective compared to azacitidine alone.
For: Myelodysplastic Syndrome (MDS)United States · Australia · Austria - Active not recruitingPHASE3
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
This study compares two treatments, Venetoclax plus Dexamethasone, and Pomalidomide plus Dexamethasone, for people with a specific type of multiple myeloma (t(11;14)-positive) that has come back or not responded to previous treatments. It aims to see which treatment works best at preventing the disease from getting worse.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE2
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
This study looks at a new way to re-treat a type of blood cancer called CLL when it returns. It uses two approved medicines, venetoclax and obinutuzumab, in adults who have had previous venetoclax treatment.
For: Chronic Lymphocytic Leukemia (CLL)United States · Australia · Austria - RecruitingPHASE1, PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study looks at new treatments for children and young adults with specific types of blood cancer that have come back or not responded to previous treatment. It tests a combination of medicines to see if they are safe and work well for those whose cancer has certain genetic changes.
For: Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark - RecruitingPHASE1, PHASE2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
This study is testing a new drug, Enzomenib, for people with certain types of leukaemia or blood cancers like MDS and Multiple Myeloma. It will look at its safety and how well it works, both alone and with other common treatments.
For: Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Acute · Multiple MyelomaUnited States · Belgium · Canada - RecruitingPHASE1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study looks at a new treatment called mosunetuzumab for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It checks how safe it is, how well it works, and how the body handles it, sometimes used with another drug, venetoclax.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · China - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - Active not recruitingPHASE1, PHASE2
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This study is testing a new drug, IMGN632, for adults with a type of blood cancer called Acute Myeloid Leukemia (AML). It's looking at whether IMGN632 is safe and effective when given alone or with other common AML treatments.
For: Acute Myeloid LeukemiaUnited States · France · Germany - RecruitingPHASE2, PHASE3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
This study is testing new ways to treat certain blood cancers, like some types of leukaemia and myelodysplastic syndromes. Researchers are looking at a new drug, ASTX030, sometimes with another drug called venetoclax, to see if it's safe and works better than current treatments.
For: Myelodysplastic Syndromes · Acute Myeloid Leukemia · Myelodysplastic Syndrome/NeoplasmUnited States · Canada · Czechia - Active not recruitingPHASE3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
This study compares two treatments for chronic lymphocytic leukaemia (CLL), a type of blood cancer. We're looking at whether a new combination (sonrotoclax with zanubrutinib) works better than a standard one (venetoclax with obinutuzumab) in people who haven't had treatment before.
For: CLLUnited States · Australia · Austria - RecruitingPHASE3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
This study is looking at a new combination of treatments for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares a new drug called Nemtabrutinib with Venetoclax against a standard treatment, to see if the new combination is better at stopping the cancer from growing.
For: Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Chronic Lymphocytic · Small-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This study looks at new ways to treat Chronic Lymphocytic Leukemia (CLL), a type of blood cancer. Researchers are testing the safety of two drug combinations: venetoclax with obinutuzumab, or venetoclax with acalabrutinib. They want to see how well these treatments work and if they cause any side effects.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · France - Active not recruitingPHASE1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
This study is looking into a new medicine, ABBV-101, for blood cancers called non-Hodgkin's lymphoma (NHL). It will check how safe the medicine is, how it moves through the body, and if it helps people with different types of NHL that have come back or not responded to other treatments.
For: Hematologic CancerUnited States · Canada · France - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070)
This study is for adults with a type of blood cancer called AML that has come back or not responded to usual treatments. It's testing a new combination of medicines to see if it's safe and helps more people. It combines standard chemotherapy drugs with a newer drug called venetoclax.
Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
This study looks at new ways to treat acute myeloid leukaemia (AML) after a stem cell transplant. It combines two medicines, venetoclax and azacitidine, to see if they are safe and help people live longer and healthier lives after their transplant.
For: Acute Myeloid LeukaemiaCzechia · Hungary · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy
This study looks at a new drug, tamibarotene, combined with venetoclax and azacitidine, for adults with a specific type of acute myeloid leukaemia (AML) who can't have standard treatment. It aims to see how safe the combination is and if it makes the cancer go into remission.
For: RARA-positive acute myeloid leukemiaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
HOVON 139 CLL: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial).
This study looks at new ways to treat chronic lymphocytic leukaemia (CLL). It combines a medicine called obinutuzumab with venetoclax to see if it helps patients who can't have standard chemotherapy. Researchers want to find out how well it works and if it can clear all signs of the cancer.
For: Chronic lymphocytic leukemiaNetherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
This study looks at a new combination treatment for acute myeloid leukaemia (AML) in people who can't have strong chemotherapy. It compares a drug called Venetoclax plus a low-dose chemotherapy called Cytarabine, to just low-dose Cytarabine on its own, to see which is more effective.
For: Acute Myeloid LeukemiaFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy, Incorporating Extension Period - Continued Access for Venetoclax. (VIALE-A)
This study looks at a new treatment called venetoclax combined with an existing medicine called azacitidine for people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to see if this combination works better than azacitidine alone for patients who can't have standard strong chemotherapy.
For: Acute Myeloid LeukemiaFinland · Czechia · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)
This study is looking at a new treatment combination — rituximab, bendamustine, cytarabine, and venetoclax (V-RBAC) — for older patients with a specific type of blood cancer called mantle cell lymphoma. It aims to see how well this new treatment stops the cancer from growing for at least two years.
For: Mantle Cell LymphomaItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refractory Acute Myeloid Leukemia and in Combination with 5-Azacytidine and Venetoclax for Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Negative for NPM1 and IDH 1/2 Mutations Who Are Ineligible for Intensive Chemotherapy (AARON)
This study looks at new drug combinations for acute myeloid leukaemia (AML). It aims to find the safest dose and see how well these combinations work in people whose AML has come back or not responded to treatment, and in newly diagnosed patients who can't have strong chemotherapy.
For: Acute Myeloid LeukemiaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Venetoclax after TKI to target persisting stem cells in CML
This study looks at a new way to treat Chronic Myeloid Leukaemia (CML). It's for people whose CML is well controlled with standard medicine. Researchers want to see if adding another drug, Venetoclax, can get rid of the remaining leukaemia cells that might be hiding in the bone marrow.
For: Chronic Myeloid LeukemiaGermany - Active not recruitingPHASE1
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
This study looks at a new combination treatment, venetoclax and azacitidine, for people in the UK with a higher-risk type of blood cancer called Myelodysplastic Syndromes (MDS) who haven't had treatment before. It's an early-stage study to find the best dose.
For: Myelodysplastic Syndromes (MDS)United States · Australia · Canada - RecruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
For: Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark - Active not recruitingPHASE3
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This study compares a new treatment, Pirtobrutinib, with standard drugs (Venetoclax and Rituximab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who’ve had treatment before. Researchers want to see if the new combination works better and is safe.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
This study looks at new drug combinations for people with newly diagnosed chronic lymphocytic leukemia (CLL). It compares these new treatments, acalabrutinib and venetoclax (with or without obinutuzumab), to standard chemotherapy to see which works best and is safest.
For: Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia